Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVR AlloVir	$2.60 +4.4%	$3.96	$7.96 ▼ $24.15	$13.11M	0.63	16,830 shs	28,792 shs
ATNM Actinium Pharmaceuticals	$1.62 -1.8%	$1.55	$1.03 ▼ $8.64	$50.54M	-0.27	505,032 shs	404,015 shs
OSTX OS Therapies	$1.81 +2.8%	$1.75	$1.12 ▼ $7.00	$50.86M	N/A	458,945 shs	364,314 shs
PEPG PepGen	$1.28 -5.9%	$1.48	$0.88 ▼ $19.30	$44.50M	1.3	832,549 shs	300,425 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVR AlloVir	+4.42%	+1.17%	-6.81%	-71.14%	-85.11%
ATNM Actinium Pharmaceuticals	-1.82%	+10.96%	-1.82%	-10.50%	-78.02%
OSTX OS Therapies	+2.84%	-0.55%	+13.13%	+11.73%	+180,999,900.00%
PEPG PepGen	-5.88%	-12.93%	-12.93%	-13.51%	-92.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALVR AlloVir	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ATNM Actinium Pharmaceuticals	1.1811 of 5 stars	3.4	2.0	0.0	0.0	0.0	0.0	0.6
OSTX OS Therapies	2.5 of 5 stars	3.7	0.0	0.0	0.0	2.4	1.7	0.6
PEPG PepGen	2.8112 of 5 stars	3.2	3.0	0.0	0.0	1.8	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALVR AlloVir	0.00	N/A	N/A	N/A
ATNM Actinium Pharmaceuticals	2.75	Moderate Buy	$4.00	146.91% Upside
OSTX OS Therapies	3.40	Buy	$18.00	894.48% Upside
PEPG PepGen	2.33	Hold	$7.67	498.96% Upside

Current Analyst Ratings Breakdown

Latest ALVR, OSTX, PEPG, and ATNM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/24/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/9/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
5/29/2025	PEPG PepGen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $8.00
5/15/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/12/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
5/9/2025	PEPG PepGen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $14.00
4/28/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/22/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/7/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/2/2025	OSTX OS Therapies	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$19.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALVR AlloVir	N/A	N/A	N/A	N/A	$29.35 per share	N/A
ATNM Actinium Pharmaceuticals	$81K	623.92	N/A	N/A	$1.31 per share	1.24
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A	N/A
PEPG PepGen	N/A	N/A	N/A	N/A	$3.64 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALVR AlloVir	-$190.42M	-$20.23	N/A	∞	N/A	N/A	-71.03%	-61.27%	8/7/2025 (Estimated)
ATNM Actinium Pharmaceuticals	-$48.82M	-$1.39	N/A	N/A	N/A	N/A	-100.85%	-47.89%	N/A
OSTX OS Therapies	-$7.79M	-$0.86	N/A	N/A	N/A	N/A	N/A	-569.57%	N/A
PEPG PepGen	-$89.98M	-$3.13	N/A	N/A	N/A	N/A	-81.26%	-63.65%	8/6/2025 (Estimated)

Latest ALVR, OSTX, PEPG, and ATNM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	PEPG PepGen	-$0.72	-$0.92	-$0.20	-$0.92	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALVR AlloVir	N/A	N/A	N/A	N/A	N/A
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A
PEPG PepGen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALVR AlloVir	N/A	86.78	86.78
ATNM Actinium Pharmaceuticals	N/A	10.25	10.25
OSTX OS Therapies	N/A	0.76	0.76
PEPG PepGen	N/A	4.95	4.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALVR AlloVir	66.05%
ATNM Actinium Pharmaceuticals	27.50%
OSTX OS Therapies	N/A
PEPG PepGen	58.01%

Insider Ownership

Company	Insider Ownership
ALVR AlloVir	32.07%
ATNM Actinium Pharmaceuticals	6.00%
OSTX OS Therapies	13.80%
PEPG PepGen	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALVR AlloVir	110	5.04 million	3.43 million	Optionable
ATNM Actinium Pharmaceuticals	30	31.20 million	29.32 million	Optionable
OSTX OS Therapies	N/A	28.10 million	N/A	N/A
PEPG PepGen	30	32.72 million	31.02 million	Not Optionable

ALVR, OSTX, PEPG, and ATNM Headlines

Recent News About These Companies

PEPG Investors Have the Opportunity to Lead the PepGen Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

June 26 at 7:30 PM | prnewswire.com

PepGen Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 8, 2025 Deadline to file Lead Plaintiff Motion.

June 26 at 6:35 PM | globenewswire.com

PEPG Investors Have Opportunity to Lead PepGen Inc. Securities Fraud Lawsuit

June 26 at 5:10 PM | prnewswire.com

Lost Money on PepGen Inc.(PEPG)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm

June 26 at 9:00 AM | prnewswire.com

August 8, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against PEPG

June 24 at 4:14 PM | globenewswire.com

PEPG INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that PepGen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

June 24 at 4:00 PM | globenewswire.com

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen

June 24 at 11:44 AM | globenewswire.com

August 8, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against PEPG

June 24 at 9:00 AM | prnewswire.com

Investors in PepGen Inc. Should Contact The Gross Law Firm Before August 8, 2025 to Discuss Your Rights – PEPG

June 23, 2025 | globenewswire.com

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 8, 2025 in PepGen Inc. Lawsuit - PEPG

June 23, 2025 | prnewswire.com

PEPGEN INC. (NASDAQ: PEPG) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds PepGen Inc. Investors of Upcoming Deadline

June 23, 2025 | globenewswire.com

Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPG

June 22, 2025 | prnewswire.com

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PEPG

June 21, 2025 | globenewswire.com

PEPG Investors Have Opportunity to Lead PepGen Inc. Securities Fraud Lawsuit

June 20, 2025 | prnewswire.com

Faruqi & Faruqi Reminds PepGen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 - PEPG

June 20, 2025 | prnewswire.com

PepGen Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Lawsuit Against PEPG

June 20, 2025 | prnewswire.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 8, 2025 in PepGen Inc. Lawsuit - PEPG

June 20, 2025 | prnewswire.com

Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers – PEPG

June 19, 2025 | morningstar.comM

The Gross Law Firm Notifies PepGen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - PEPG

June 19, 2025 | prnewswire.com

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against PepGen Inc. (NASDAQ: PEPG)

June 19, 2025 | globenewswire.com

PepGen (NASDAQ:PEPG) Given New $8.00 Price Target at HC Wainwright

May 30, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVR, OSTX, PEPG, and ATNM Company Descriptions

AlloVir NASDAQ:ALVR

$2.60 +0.11 (+4.42%)

As of 06/25/2025

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Actinium Pharmaceuticals NYSE:ATNM

$1.62 -0.03 (-1.82%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$1.62 0.00 (0.00%)

As of 04:05 AM Eastern

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

OS Therapies NYSE:OSTX

$1.81 +0.05 (+2.84%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$1.85 +0.04 (+2.43%)

As of 04:31 AM Eastern

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

PepGen NASDAQ:PEPG

$1.28 -0.08 (-5.88%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$1.47 +0.19 (+14.84%)

As of 04:32 AM Eastern

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time